Related Experiment Video
Updated: May 5, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
Published on: April 14, 2014
Bilateral Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) Optic Neuritis: A Case
Nadhirah Ahmad Fauzi1, Abd Bari Muhd-Syafi1, Abdul Hadi Rosli1
1Ophthalmology, International Islamic University Malaysia, Kuantan, MYS.
Abstract:
Optic neuritis (ON) is defined as an acquired disorder of the optic nerve that may be associated with demyelinating diseases or infectious or inflammatory processes. In children, the manifestation of this condition differs from that in adults, where it typically presents with bilateral papillitis subsequent to a preceding viral illness. Nonetheless, the main concern for practitioners is the possibility of its conversion to multiple sclerosis (MS). In recent years, there has been increased awareness regarding differentiating MS from other demyelinating ON phenotypes, namely, neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Despite the clinical similarities among these three entities, they vary in terms of pathophysiology, clinical course, treatment approaches, and prognostication. In this paper, we highlight the case of a child with MOGAD ON who was clinically severe at presentation and has typical features of ON and the appropriate investigation and treatment done to achieve complete visual recovery.
More Related Videos
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
07:50A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Related Concept Videos
Glaucoma: Overview
Arboviral Encephalitis
Cytomegalovirus Disease
Bacterial Meningitis I: Introduction
Bacterial Meningitis II: Pathophysiology
Myasthenia Gravis ll: Pathophysiology